NCT02806414: A reported trial by University of California, San Diego
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02806414 |
|---|---|
| Title | A Single Site Evaluation of the Inhibitory Effects of Topical Ivermectin on Serine Protease Activity and Production of LL-37 Cathelicidin Peptide, Biochemical Markers of Rosacea-specific Inflammation and on the Skin Microbiome in Rosacea. |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | July 31, 2016 |
| Completion date | July 31, 2019 |
| Required reporting date | July 30, 2020, midnight |
| Actual reporting date | June 15, 2020 |
| Date last checked at ClinicalTrials.gov | March 28, 2025 |
| Days late | None |